Takeda Pharmaceutical Co. Ltd.

Plus: Creyon/Lilly, Concentra/Kronos, Novavax/Takeda and more

An advancing wave of new candidates, spanning diverse modalities, converges with push for surrogate endpoint status

Plus: Oak Hill reviving Roche program for Angelman syndrome

With clinical records, patient samples and images in the millions, the diagnostics and data company is betting precision medicine can go multimodal

Leaving past limitations behind, Danish pharma widens its technology aperture to brain shuttles, AI and more  

Plus: Jon Garay Alonso named CFO of Almirall, and updates from Certara and Immunai

Bright spot was a slight rise in Protagonist shares on polycythemia vera results

Plus: Hummingbird/Callio, Bridgene/Takeda, Magnet/Lilly, Gensaic/Novo, and more

Plus: Jeffrey Sevigny named CMO of Rapport, and updates from Garuda, Metis, Ovid and more

As the first Dravet syndrome products establish the market, the pipeline moves toward selective small molecules and genetic therapies